Kinetic mRNA Profiling in a Rat Model of Left-Ventricular Hypertrophy Reveals Early Expression of Chemokines and Their Receptors by Nemska, Simona et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
Kinetic mRNA Profiling in a Rat Model of Left-Ventricular Hypertrophy
Reveals Early Expression of Chemokines and Their Receptors
Nemska, Simona; Monassier, Laurent; Gassmann, Max; Frossard, Nelly; Tavakoli, Reza
Abstract: Left-ventricular hypertrophy (LVH), a risk factor for heart failure and death, is character-
ized by cardiomyocyte hypertrophy, interstitial cell proliferation, and leukocyte infiltration. Chemokines
interacting with G protein-coupled chemokine receptors may play a role in LVH development by pro-
moting recruitment of activated leukocytes or modulating left-ventricular remodeling. Using a pressure
overload-induced kinetic model of LVH in rats, we examined during 14 days the expression over time
of chemokine and chemokine receptor mRNAs in left ventricles from aortic-banded vs sham-operated
animals. Two phases were clearly distinguished: an inflammatory phase (D3-D5) with overexpression of
inflammatory genes such as il-1ß, tnfa, nlrp3, and the rela subunit of nf-kb, and a hypertrophic phase
(D7-D14) where anp overexpression was accompanied by a heart weight/body weight ratio that increased
by more than 20% at D14. No cardiac dysfunction was detectable by echocardiography at the latter
time point. Of the 36 chemokines and 20 chemokine receptors analyzed by a Taqman Low Density Array
panel, we identified at D3 (the early inflammatory phase) overexpression of mRNAs for the monocyte
chemotactic proteins CCL2 (12-fold increase), CCL7 (7-fold increase), and CCL12 (3-fold increase), for
the macrophage inflammatory proteins CCL3 (4-fold increase), CCL4 (2-fold increase), and CCL9 (2-fold
increase), for their receptors CCR2 (4-fold increase), CCR1 (3-fold increase), and CCR5 (3-fold increase),
and for CXCL1 (8-fold increase) and CXCL16 (2-fold increase). During the hypertrophic phase mRNA
expression of chemokines and receptors returned to the baseline levels observed at D0. Hence, this first
exhaustive study of chemokine and chemokine receptor mRNA expression kinetics reports early expres-
sion of monocyte/macrophage-related chemokines and their receptors during the development of LVH in
rats, followed by regulation of inflammation as LVH progresses.
DOI: 10.1371/journal.pone.0161273
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-125811
Veröffentlichte Version
Originally published at:
Nemska, Simona; Monassier, Laurent; Gassmann, Max; Frossard, Nelly; Tavakoli, Reza (2016). Kinetic
mRNA Profiling in a Rat Model of Left-Ventricular Hypertrophy Reveals Early Expression of Chemokines
and Their Receptors. PLoS ONE, 11(8):e0161273. DOI: 10.1371/journal.pone.0161273
RESEARCH ARTICLE
Kinetic mRNA Profiling in a Rat Model of Left-
Ventricular Hypertrophy Reveals Early
Expression of Chemokines and Their
Receptors
Simona Nemska1,2, Laurent Monassier3, Max Gassmann1, Nelly Frossard2*,
Reza Tavakoli1,4*
1 Institute of Veterinary Physiology and Zurich Center of Integrative Human Physiology, University of Zurich,
Zurich, Switzerland, 2 Laboratoire d’Innovation Thérapeutique, UMR7200, Université de Strasbourg—
CNRS, Strasbourg, France, 3 Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire EA7296,
Fédération de Médecine Translationnelle, Université de Strasbourg, Strasbourg, France, 4 Department of
Cardiac Surgery, Canton Hospital Lucerne, Lucerne, Switzerland
* reza.tavakoli@uzh.ch (RT); nelly.frossard@unistra.fr (NF)
Abstract
Left-ventricular hypertrophy (LVH), a risk factor for heart failure and death, is characterized
by cardiomyocyte hypertrophy, interstitial cell proliferation, and leukocyte infiltration. Che-
mokines interacting with G protein-coupled chemokine receptors may play a role in LVH
development by promoting recruitment of activated leukocytes or modulating left-ventricular
remodeling. Using a pressure overload-induced kinetic model of LVH in rats, we examined
during 14 days the expression over time of chemokine and chemokine receptor mRNAs in
left ventricles from aortic-banded vs sham-operated animals. Two phases were clearly dis-
tinguished: an inflammatory phase (D3-D5) with overexpression of inflammatory genes
such as il-1ß, tnfa, nlrp3, and the rela subunit of nf-kb, and a hypertrophic phase (D7-D14)
where anp overexpression was accompanied by a heart weight/body weight ratio that
increased by more than 20% at D14. No cardiac dysfunction was detectable by echocardi-
ography at the latter time point. Of the 36 chemokines and 20 chemokine receptors ana-
lyzed by a Taqman Low Density Array panel, we identified at D3 (the early inflammatory
phase) overexpression of mRNAs for the monocyte chemotactic proteins CCL2 (12-fold
increase), CCL7 (7-fold increase), and CCL12 (3-fold increase), for the macrophage inflam-
matory proteins CCL3 (4-fold increase), CCL4 (2-fold increase), and CCL9 (2-fold
increase), for their receptors CCR2 (4-fold increase), CCR1 (3-fold increase), and CCR5 (3-
fold increase), and for CXCL1 (8-fold increase) and CXCL16 (2-fold increase). During the
hypertrophic phase mRNA expression of chemokines and receptors returned to the base-
line levels observed at D0. Hence, this first exhaustive study of chemokine and chemokine
receptor mRNA expression kinetics reports early expression of monocyte/macrophage-
related chemokines and their receptors during the development of LVH in rats, followed by
regulation of inflammation as LVH progresses.
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Introduction
Left-ventricular hypertrophy (LVH) commonly follows chronic pressure or volume overload
in diseases such as essential arterial hypertension and aortic valve stenosis. Insufficient relief of
the left-ventricular workload will ultimately result in an irreversible state of cardiac dysfunction
leading to arrhythmias, heart failure, or even death. Numerous stress stimuli can increase car-
diomyocyte protein synthesis and cell volume [1–3]; these changes are accompanied by energy
metabolism deficits, vascular dysfunction, and alterations of the extracellular matrix composi-
tion [4–6]. In addition, pressure overload causes interstitial cell proliferation (vascular smooth
muscle and endothelial cells and fibroblasts) that causes increased vascular stiffness [7, 8],
accompanied by inflammatory signals generated by the vessel wall (endothelium) [9–11]. The
role of inflammatory response in cardiac hypertrophy was first suggested by in vitro studies of
rat neonatal cardiomyocytes, where activation and nuclear translocation of NF-kB (nuclear fac-
tor kB) are required for hypertrophic cardiomyocyte growth [12, 13]. Macrophages and neu-
trophils are reported to accumulate in the hypertrophic left ventricle of a mouse model of
aortic constriction 3–6 days after surgery [14, 15]. Similarly, the observation of newly recruited
leukocytes in biopsies from hypertrophic hearts of patients with aortic valve stenosis suggests
that hypertrophy is associated with a persistent proinflammatory response [16], which in turn
has been related to the production of profibrotic factors (TGF-ß, transforming growth factor-
ß) by newly infiltrated immune cells [17, 18].
In proinflammatory disease conditions, the trafficking of immune cells to sites where
inflammatory stress is occurring is regulated mainly by the action of chemokines binding to
their G protein-coupled receptors (GPCR) [19–21]. In cardiac hypertrophy, upregulated
expression of a small number of chemokines is reported both in animal models [22, 23] and in
patients with cardiac hypertrophy [24–26]. Elevated levels of CCL2 are found in cardiac biop-
sies from patients with cardiac hypertrophy due to aortic stenosis [16]. Similarly, CXCL16 is
found at high levels in the plasma of patients with right-ventricular hypertrophy due to pulmo-
nary stenosis and those with LVH in heart failure [27, 28]; in the latter case, expression levels
correlated with disease severity. In addition, CX3CL1, an atypical chemokine that, like
CXCL16, exists in both membrane-bound and soluble forms, is also detected in hearts and
serum of patients with heart failure [26, 29]. Levels of circulating CCL2, CCL3, and CCL5 che-
mokines are high in patients with cardiac hypertrophy and congestive heart failure [24], and
CCL21 is found at significantly higher than normal levels in the serum of patients with LVH
due to aortic stenosis and pressure overload [30]. Finally, high CXCL12 plasma levels are
found in patients with hypertrophic cardiomyopathy, LVH, and heart failure, and CXCL12-de-
pendent fibrocyte migration increases when diffuse fibrosis is present [31, 32]. These data sug-
gest that chemokine and chemokine receptor interactions play a pivotal role in the
establishment of cardiac hypertrophy.
To obtain deeper insight into the molecular factors associated with LVH development, we
undertook a comprehensive analysis of mRNA expression of chemokines and their receptors
in the initiation and progression phases of cardiac hypertrophy in a rat model of aortic
banding.
Material and Methods
Animals
Male Lewis rats weighing 100–110 g were purchased from Janvier (Le Genest-Saint-Isle,
France) and maintained on a 12/12-hour light/dark cycle, in standard T3 cages, with food and
water available ad libitum. In this protocol no analgesia or antibiotics were given as the opioid
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analgesics and anti-inflammatory drugs may impair the inflammatory response during hyper-
trophy. Antibiotics can alter the expression of chemokines, which might interfere with our
results [33, 34]. Animal experimentation was performed in accordance with the national guide-
lines, and the protocols were approved by the "Strasbourg Regional Ethics Committee for Ani-
mal Experimentation CREMEAS” (#02438.01) in accordance with European regulations.
Aortic banding
Aortic banding was performed as described [3]. Briefly, rats were anesthetized by pentobarbital
(Ceva, 6742145; 50 mg/kg i.p. in saline). After laparotomy, a polyurethane ring 1 mm in diame-
ter was placed around the suprarenal abdominal aorta to create stenosis. Sham operations were
performed without ring placement. The abdominal wall was sutured with a 4.0 surgical suture
(Ethicon, USA). After operation, animals are placed on a heating plate (35°C) until they wake
up. Rats were then kept individually in T3 cages. The survival rate in this study was 88%; four-
teen of the animals (all from aortic-banded group) died during the experiment. Five out of 14
animals did not wake up after surgery and died from technical surgical failure on day (D) 0 of
surgery. Five rats were found unexpectedly dead in the morning on D4-D6 post-operation.
Four rats had to be euthanized by 100 mg/Kg pentobarbital because of unhealthy appearance
with red and sunken eyes, ruffled hair, hunched body and/or changes in the locomotion on
D4-D6 post-operation, most probably due to hypertensive crisis. Animal monitoring was per-
formed twice a day. Body weight did not differ at any point during the study between these rats
and the sham-operated group. Hearts were harvested on D0, 1, 3, 5, 7, and 14 from n = 6 rats
in each group; their atria were removed and the ventricles weighed. Right ventricles were
removed and a transversal slice of the left ventricle (LV) was cut and paraffin-embedded for
histological study. The remaining part of the LV was frozen in liquid nitrogen for biochemical
analyses.
Echocardiography
Serial echocardiographic-Doppler assessment of cardiac anatomy, function, and hemodynam-
ics was performed on D0, 1, 3, 5, 7, and 14 after operation (n = 6 per group). Rats were weighed,
anesthetized by pentobarbital (40 mg/kg i.p.), and studied with a Sonos 5500 echocardiography
machine (Philips, USA) equipped with a 12-MHz sectorial transducer. The animal's body tem-
perature was maintained at 37°C with a controlled heating pad (homeothermic blanket control
unit, Harvard Apparatus). Interventricular septum and posterior wall thickness were measured
on the parasternal short-axis view of the LV in diastole. The end-diastolic and end-systolic left
ventricle diameters (EDLVD and ESLVD) were measured on the parasternal LV short-axis
view fromM-mode. The fractional shortening (FS = [(EDLVD-ESLVD) / EDLVD] x100) and
the ejection fraction (EF = [(EDLVD3-ESLVD3)/EDLVD3] x 100) were calculated. All mea-
sured and calculated indices are means of four consecutive beats.
Histology
A transversal slice from the basal part of the LV tissue (n = 6 per group) was fixed in parafor-
maldehyde 4% for 24 h and paraffin-embedded after successive lavages in ethanol (70–100%)
for 1 h each and incubation in xylene for 3 h. Then 5-μm sections were cut and mounted on
Superfrost glass slides (Fisher Scientific). After deparaffinization in xylene and successive rehy-
dration, sections were stained with hematoxylin-eosin. The LV wall area and the LV cross-sec-
tional thickness (15 measurements for each section) were measured with ImageJ 1.47v
software. Sections were observed on a Leica DM4000B microscope with an Olympus DP72
camera and analyzed with CellSensDimension software.
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RNA extraction, reverse transcription, and qPCR
Total RNA was extracted both from the apex and the base of the LV (30–40 mg tissue for each)
with TriReagent1 (Euromedex) and purified after binding on silica columns under high-salt
conditions (RNeasy Mini kit, Qiagen). RNA quantity and purity were assessed by absorption
spectra analysis (Nanodrop1) and fluorescence absorption (Qubit1 Fluorimetric RNA assay,
Invitrogen). RNA quality was evaluated by the absorption ratios A260/A280 and A260/A230
between 1.8 and 2.2. The concentration ratio between Qubit1 and Nanodrop1 ranged from
0.9 to 1.1. RNA integrity was analyzed with the Agilent 2100 Bioanalyzer with an RNA 6000
Chip and 2100 Expert software (Agilent Technologies). All samples had an RNA integrity
number higher than 8. RNA (1 µg) was then reverse-transcribed with the high-capacity cDNA
Reverse Transcription kit containing MultiScribe Reverse Transcriptase from the murine
moloney leukemia virus (Applied Biosystems). Real-time qPCR was performed on the ABIPr-
ism 7900 Thermocycler (Applied Biosystems) with 384-well Taqman Low Density arrays
(Applied Biosystems) designed for the analysis of the 36 chemokines and 20 chemokine recep-
tors for which primers were then available for rats (S1 Table). We also analyzed nine inflamma-
tory genes (crp (c-reactive protein), il-1ß (interleukin-1ß), il-6, il-17a, ifng (interferon g), tnfa
(tumor necrosis factor a), nlrp3 (NOD-like receptor family, pyrin domain containing 3), scf
(stem cell factor, kit ligand), and rela) and five housekeeping genes: gapdh (glyceraldehyde-
3-phosphate dehydrogenase), 18S, hprt1 (hypoxanthine phosphoribosyltransferase), hmbs
(hydroxyl-methylbilane synthase), and tbp (TATA box binding protein) (S1 Table). The stabil-
ity of the reference genes was analyzed (DataAssist1, Applied Biosystems), with lower scores
indicating more stable reference genes [35]. The lowest score was observed for gapdh (0.84).
Other samples showing good Ct stability were 18S (0.89), hprt1 (0.89), and hmbs (0.86) (S1
Fig). The only unsatisfactory score was 2.22 for tbp. Results were therefore referenced to the
most stable gene, gapdh, and compared to those referenced to the geometric mean of the 4 sta-
ble genes: both analyses showed similar results. The endogenous regulators of cardiac hypertro-
phy anp (atrial natriuretic peptide) and bnp (brain natriuretic peptide) were used as positive
controls for the hypertrophic phenotype. The cutoff for gene expression was set at Ct<32.
Results are presented as mean mRNA expression in the qPCR results from each part of the LV
base and apex.
Data analysis and statistics
Statistical analyses were performed by one-way ANOVA followed by Bonferroni‘s multiple
comparison tests. Differences in the LV area and wall thickness for the two groups were com-
pared by a t-test. Means were considered statistically significantly different when P<0.05.
Results
Inflammation occurs before hypertrophy in the rat LVHmodel
We performed a kinetic study of the mRNA expression of pro-inflammatory and pro-hyper-
trophic genes in the aortic-banded model. At D0, the pro-inflammatory genes il-1ß, tnfa, nlrp3,
scf, and rela were expressed both in aortic-banded and sham groups (Ct<32), whereas crp, il-6,
il-17a, and ifng were not (Fig 1A). At D3, expression of IL-1ß and TNFa mRNA increased by
3.4±1.5-fold (P<0.01) and 1.9±0.6-fold (P<0.05), respectively, in aortic-banded vs sham-oper-
ated animals (Fig 1A). NLRP3 mRNA that encodes a protein of the inflammasome, also
increased at D3 by 1.9±0.5-fold (P<0.05) (Fig 1A). At D5, expression of the RelA subunit of
NF-kB was 1.7±0.4-fold higher in the aortic-banded rats (P<0.05). Expression of SCF did not
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change over time and between aortic-banded and sham-operated animals (e.g. 0.88±0.14-fold
at D3 and 1.08±0.11-fold at D5) (S2 Fig).
In contrast to the expression of inflammatory genes that peaked at D3 or D5, the expression
of ANP mRNA the endogenous hypertrophic marker, increased progressively in the aortic-
banded vs sham-operated groups, with statistically significantly higher levels at D5 (50
±24-fold, P<0.001), decreasing at D7 (34±20-fold, P<0.01) and D14 (18±9-fold, P<0.01) (Fig
1B). BNP mRNA expression, another positive control for cardiac hypertrophy, also increased
significantly in the aortic-banded vs sham-operated groups, with statistically higher levels at
D3 (7.3±2.9-fold, P<0.001), at D5 (3.6±1.1-fold, P<0.05), at D7 (3.2±0.6-fold, P<0.05) and at
D14 (3.7±1-fold, P<0.01) (Fig 1B). The manifestation of hypertrophy at this later phase was
confirmed macroscopically by the heart weight/body weight ratio that increased progressively
over time in the aortic-banded vs the sham-operated group (Fig 2A): it was significantly higher
at D7 (15.9% increase, P<0.05) and D14 (20.4% increase, P<0.001). LVH at this later stage
was visualized by histological analysis of the LV wall area and thickness, which were signifi-
cantly larger in the aortic-banded (41.6±1.9 mm2 and 1.9±0.1 mm, respectively) than the
sham-operated animals (34.0±1.0 mm2 and 1.6±0.1 mm, P<0.05 for both; Fig 2B and 2C). Fig
2D presents the hematoxylin-eosin staining of LV sections from sham-operated and aortic-
banded animals at D14, and S3 Fig at D0-D7. Data for LV wall area and thickness over time are
presented in S2 Table. Echocardiographic values of the interventricular septum and posterior
wall thickness of the LV in diastole at D14 confirmed significantly higher measurements in the
aortic-banded (1.24±0.03 and 1.12±0.02 mm, respectively) vs sham-operated groups (0.97
±0.02 and 0.83±0.02 mm) (P<0.001 for both, S4 Fig). The results indicate concentric LVH in
this model. None of the animals developed cardiac dysfunction, as the shortening (FS) and
ejection fractions (EF) did not differ significantly between the two groups and remained within
the normal range (FS> 40% and EF> 75%) (Fig 2E). These findings suggest that the
Fig 1. Inflammatory and hypertrophic genesmRNA expression in rat LVH. (A) mRNA overexpression of inflammatory genes in aortic-banded vs
sham-operated groups (n = 6 per group). (B) mRNA expression of the atrial natriuretic protein (ANP) and of the brain natriuretic peptide (BNP), positive
controls for cardiac hypertrophy in aortic-banded vs sham-operated animals (n = 6 per group). Expression is calculated as 2(-ΔCt) where the calibrator is
the mRNA level of the gapdh reference gene. Data are presented as mean ± SEM. *P<0.05 **P<0.01 compared to sham group.
doi:10.1371/journal.pone.0161273.g001
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Fig 2. Left ventricle anatomy and function in rat LVH. (A) Heart (left and right ventricles) to body weight ratio (mg/g) in
aortic-banded (black line) vs sham-operated animals (gray line) from D0 to D14 (n = 6 per group). (B) Left ventricle area in
sham-operated (gray block) vs aortic-banded (black block) animals (n = 6 per group) at D14. (C) Left-ventricle wall thickness
in aortic banded vs sham-operated groups (n = 6 per group). (D) Hematoxylin-eosin staining of left-ventricular sections from
Chemokines and Receptors in Rat LVH
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hypertrophy is compensated throughout the entire 14 days study period where the left ventricle
function is still preserved.
Expression of chemokine mRNAs in rat LVH
Of the 36 chemokine genes studied, 13 chemokines were not expressed in any animals at any
time point (Ct>32) (S1 Table). The 23 mRNAs that were expressed (Ct<32) were analyzed
and compared over time (D0, D1, D3, D5, D7, and D14) between the two groups (Fig 3). First,
the excellent reproducibility of the chemokine mRNA levels in the sham-operated animals
over time allowed us to compare them with the aortic-banded rats. The global analysis showed
that the mean fold differences between the groups peaked at D3 (2.4±0.6) and D5 (1.6±0.2),
while chemokine levels remained relatively constant and similar at D0 (1.0±0.1), D1 (1.2±0.1),
D7 (1.3±0.1), and D14 (1.2±0.1) (S5A Fig). This indicates that overexpression of chemokines
in the aortic-banded animals occurred at D3 and D5 post-surgery and normalized thereafter
even as LVH progressed (D7-D14). The absence of overexpression of any chemokine (Fig 3) or
inflammatory gene (Fig 1) at D14, the end point, indicates that their expression remained regu-
lated during the compensated phase of LVH.
Fig 4 shows a selection of the overexpressed chemokines (2-ΔCt values) in the aortic-banded
vs. sham-operated groups. CCL2 (12.2±7.2-fold, P<0.01), CCL7 (7.1±3.8-fold, p<0.001),
CCL3 (3.8±1.9-fold, P<0.001), CXCL1 (7.9±5.7-fold, P<0.001), CCL12 (2.6±1.2-fold,
P<0.05), CCL4 (1.8±0.6-fold, P<0.01) and CXCL16 (1.8±0.4-fold, P<0.05) were significantly
overexpressed at D3, but decreased thereafter. Overexpression of CCL9 continued longer: at
D3 (2.0±1.0-fold, P<0.05) and D5 (3.0±1.1-fold, P<0.05), but recovered slightly, returning to
baseline levels in both groups. CCL27 overexpression occurred later on, 2.2±0.8-fold higher on
sham operation (left) vs aortic banding (right) samples at D14. LV: Left ventricle. IVS: Interventricular septum. (E)
Echocardiography measurements of the shortening and ejection fractions, calculated as: FS = [(EDLVD-ESLVD)/EDLVD)]
x100; EF = [(EDLVD3-ESLVD3) / EDLVD3] x100. The end-diastolic and end-systolic left ventricle diameters (EDLVD and
ESLVD) were measured on parasternal short-axis view of LV fromM-mode. Data are presented as means ± SEM. *P<0.05
**P<0.01 ***P<0.001 compared to sham group.
doi:10.1371/journal.pone.0161273.g002
Fig 3. Relative mRNA expression levels of chemokines in aortic banding groups at D0, D1, D3, D5, D7, and D14. Fold change is calculated as
2(-ΔΔCt) where the calibrator is the mRNA level of the gene in the sham group. Only genes for which Ct is <32 are presented. For each sample, two
qPCRs were performed on different parts of the LV, one from the apex, and another from the base part. Means are calculated for each animal (n = 6 per
group). Fold change levels are represented on a logarithmic scale. Data are means (blocks) ± SEM (bars) of n = 6 animals.
doi:10.1371/journal.pone.0161273.g003
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D5 (P<0.05) after more scattered levels on D3 (Fig 4). Two chemokines showed significantly
higher levels at D14 in the aortic-banded group (Fig 3), although the fold difference did not
exceed 1.5: CCL19 with 1.4±0.1-fold (P<0.05) and CCL21 with 1.5±0.1-fold (P<0.05). Only
one gene in the entire study, cxcl11, showed downregulation—slight but significant—in the
aortic-banded compared to sham-operated animals, with a 0.5±0.1-fold decrease at D3
(P<0.01) and 0.7±0.1-fold at D5 (P<0.01) (Fig 4).
Expression of chemokine receptor mRNAs in rat LVH
Nine of the 20 chemokine receptors studied were not expressed in any animals at any point
(Ct>32) (S1 Table). The global analysis of chemokine receptors showed that the mean fold dif-
ference between the aortic-banded and sham-operated groups peaked at D3 (2.3±0.4) and D5
(1.8±0.2), but remained relatively constant and similar at D0 (1.2±0.4), D1 (1.2±01), D7 (1.5
±0.2), and D14 (1.2±0.1) (S5B Fig). This profile is thus similar to that for chemokine expres-
sion: the highest overexpression took place during the inflammatory phase (D3-D5), before the
presence of LVH (Fig 5).
Levels of CCR1 (3.3±1.1-fold, P<0.01), CCR2 (4.4±2.3-fold, P<0.01), CCR5 (3.0±1.3-fold,
P<0.01) and CXCR2 (4.2±2.5-fold, P<0.01) were significantly higher at D3 in the aortic-banded as
compared to sham-operated groups and decreased thereafter (Fig 6). Only CX3CR1 was signifi-
cantly overexpressed over time in the banded group, at levels more than three times higher than in
the sham-operated animals from D3 through D7: D3 (3.5±2.2-fold, P<0.05), D5 (3.5±1.1-fold,
P<0.05), and D7 (3.3±1.6-fold, P<0.05), with normalized expression thereafter (D14) (Fig 6).
Discussion
Our study reports the first exhaustive analysis of the kinetics of chemokine and chemokine
receptor mRNA expression during the development of LVH in the rat. The aortic-banded rat
model is one of the most reliable and reproducible models of LVH: aortic constriction leads to
pressure overload and to a left-ventricular hypertrophic phenotype detectable from D7. Our
kinetic study reports analyses on D0, D1, D3, D5, D7, and D14 in both groups. Results clearly
show the presence of an early inflammatory phase in the first 3–5 days after aortic banding,
Fig 4. mRNA overexpression of chemokines in aortic-banded vs sham-operated groups. Expression is calculated as 2(-ΔCt) where the calibrator
is the mRNA level of the gapdh reference gene. Data are presented as means (blocks) ± SEM (bars). *P<0.05 **P<0.01 ***P<0.001 compared to
sham group.
doi:10.1371/journal.pone.0161273.g004
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characterized by increased mRNA expression of IL-1ß, TNFa, NLRP3, and the RelA subunit of
NF-kB. This inflammatory phase is associated with overexpression of chemokines mRNA
(CCL2, CCL3, CCL4, CCL7, CCL9, and CCL12, and CXCL1 and CXCL16) and of chemokine
receptors (CCR1, CCR2, CCR5, CXCR2, CX3CR1). The inflammatory phase is followed by the
hypertrophy phase (D7-D14) characterized by ANP and BNP mRNA overexpression, during
which time chemokine and receptor expression return to baseline levels (D0). This phase coin-
cides with the physiological compensated phase of hypertrophy in our model, as seen from the
echocardiographic measurements.
Among the panel of genes found to be overexpressed during the inflammatory phase in our
model, are the monocyte chemoattractant proteins MCP1, 3, and 5 (ccl2, 7, and 12), together
with the macrophage inflammatory proteins MIP1a, ß, and g (ccl3, 4, and 9). Their primary
function is the recruitment to the inflammation site of monocytes/macrophages, expressing
their respective chemokine receptors (CCR1, 2, 3, 5) [36–38]. CCL2/MCP1 is the chemokine
that has been studied most often in the hypertrophic heart. Elevated levels are found in the car-
diac biopsies of patients with aortic stenosis, correlated with newly recruited leukocytes [16].
Fibrosis in CCL2 KO mice is attenuated at D5 and D7 in an ischemic cardiomyopathy model
developed by intermittent daily induction of ischemia/reperfusion [22]. In parallel, invalidation
Fig 6. mRNA overexpression of chemokine receptors in aortic-banded vs sham-operated groups. Expression is calculated as 2(-ΔCt) where the
calibrator is the mRNA level of the gapdh reference gene. Data are represented as means (blocks) ± SEM (bars). *P<0.05 **P<0.01 compared to sham
group.
doi:10.1371/journal.pone.0161273.g006
Fig 5. Relative mRNA expression levels of chemokine receptors in aortic banding groups at D0, D1, D3, D5, D7, and D14. Fold change is
calculated as 2(-ΔΔCt) where the calibrator is the mRNA level of the gene in the sham group. Only genes for which the Ct is <32 are presented. For each
sample, two qPCRs are performed on different parts of the LV, one from the apex, and another from the base part. Means are calculated for each
animal (n = 6 per group). Fold change levels are represented on a logarithmic scale. Data are means (blocks) ± SEM (bars) of n = 6 animals.
doi:10.1371/journal.pone.0161273.g005
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of CCL2 by gene therapy in a murine model of left-ventricular remodeling and failure improves
survival rates and inhibits the cardiac failure characteristics associated with interstitial fibrosis
and macrophage infiltration [39]. CCL2 neutralization by anti-CCL2 blocking antibody also
leads to decreased cardiac perivascular and interstitial fibrosis, which is associated with LVH,
but does not decrease the cardiomyocyte hypertrophy itself [40]. Overexpression of CCL2 in
cardiac myocytes in alpha-cardiac myosin heavy chain (MHC)-MCP1 mice increases cardiac
monocyte recruitment and left-ventricular dysfunction [41, 42]. Consistently with these obser-
vations, in our study CCL2 mRNA was the top overexpressed chemokine—by about 12-fold—
in the aortic-banded animals, together with CCR2, the major CCL2 receptor. Our data encour-
age the investigation of the blocking effect of CCL2/CCR2 action on development of LVH.
Levels of another macrophage-attracting chemokine, CCL12/MCP-5, which also interacts
with CCR2, increased at D3 in the aortic-banded animals. CCL12 is described as a chemotactic
chemokine for inflammatory cells, such as the macrophages and fibroblast precursors
expressed during lung inflammation and infection [43–45]. To our knowledge, this study is the
first to demonstrate CCL12 mRNA expression in cardiac hypertrophy.
CCL7/MCP-3, another chemokine from the MCP family, and its receptors, CCR1 and
CCR2, were also overexpressed during the inflammatory phase in the aortic-banded animals in
our LVH model. The presence of this chemokine has not previously been reported in cardiac
hypertrophy. One of its primary functions is to mobilize monocytes from the bone marrow
(along with CCL2 activating CCR2) and promote their migration to the inflamed tissue, but it
is also critical for maintaining leukocyte homeostasis in normal conditions [46].
The macrophage inflammatory protein family mRNA was also significantly overexpressed
in the aortic-banded animals. CCL9/MIP1g, a ligand for CCR1, was overexpressed at both D3
and D5. Like the other members of the MIP chemokine family, CCL9 is chemotactic for
inflammatory monocytes [47, 48], but it has not previously been reported in LVH. CCL3/
MIP1a is inducible in a number of hematopoietic cells, particularly in those involved in adap-
tive immune responses (macrophages, dendritic cells, and B and T lymphocytes). Little infor-
mation is thus far available about its involvement in LVH, but its expression is upregulated in
serum from patients with heart failure [24]. CCL3 activates CCR1 and CCR5, both of which
were three times higher at D3 in the banded rats. Both receptors also interact with CCL4/
MIP1ß, which was slightly but significantly overexpressed (1.8-fold) in aortic-banded hearts.
This finding is in line with data from patients with aortic stenosis: CCL4 has been found to be
overexpressed in the myocardium of their hypertrophic hearts [16].
In our model, peak expression of chemokine mRNA from the MCP and MIP families coin-
cided with the timing of macrophage infiltration in left ventricles at D3 and D6, previously
reported in murine models of LVH [14, 23], and thus confirmed the inflammatory events pre-
ceding hypertrophy. Studies report the presence of both M1 and M2 macrophages in cardiac
hypertrophy: the proinflammatory M1 macrophages express miR-155 microRNA and thereby
increase the hypertrophic phenotype of cardiac tissue, while M2 macrophages are considered
to be cardioprotective [14, 49, 50]. These findings are consistent with the hypothesis of that the
M1/M2 polarization status of cardiac macrophages affects hypertrophic compensatory mecha-
nisms and adaptive responses [50].
Finally, and surprisingly, we found significant overexpression of the cutaneous CCL27 che-
mokine mRNA at D5 in the aortic-banded groups, although expression of its receptor CCR10
did not change. CCL27 is known to recruit lymphocytes to cutaneous wounds [51]; it has not
yet been demonstrated to play a role in any cardiac diseases. Further studies are required to
clarify the function of this overexpression.
Expression of a few CXC chemokine mRNA also changed over time in the aortic-banding
model. CXCL1 was overexpressed at D3, together with its receptor CXCR2. CXCL1 (GRO1,
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growth-regulated oncogene 1) is a chemoattractant for neutrophils, T lymphocytes, and mono-
cytes; it induces free radical production and thus leads to endothelial damage [52].
Another interesting group of chemokines are CXCL16 and CX3CL1 (fractalkine), both syn-
thesized as transmembrane multidomain proteins composed of a chemokine domain, a glyco-
sylated mucin-like stalk, and a single transmembrane helix [53]. Both chemokines can act as
adhesion molecules for leukocytes as well as soluble chemokines after cleavage by ADAM (A
Desintegrin And Metalloproteinase). In this study, CXCL16 mRNA was significantly overex-
pressed at D3. Its in vitro promotion of myocardial fibroblast proliferation and its augmenta-
tion of matrix metalloproteinase activity in cardiomyocytes cause it to play an important role
in hypertrophy [27]. CXCL16 and CX3CL1 together regulate expression and posttranslational
modifications of the small leucine-rich proteoglycans that regulate the extracellular matrix in
cultured cardiac fibroblasts [28]. Consistent with this observation, CXCL16 overexpression
occurs in the left-ventricular tissue of aortic-banded mice, and its upregulation is reported in
the plasma of patients with right-ventricular hypertrophy due to pulmonary valve stenosis and
heart failure; its expression levels are correlated with the severity of heart failure [28]. More-
over, studies of CXCR6 KOmice have shown that the CXCR6/CXCL16 pair plays an essential
role in the pressure overload-mediated recruitment of monocytes that contributes to cardiac
fibrosis [54]. In our model, however, mRNA expression of CXCR6 did not differ from that of
the sham-operated (control) left ventricles, nor was CX3CL1 expression in LVHmodified.
CX3CL1 expression increases in the heart and serum of patients with end-stage heart failure
due to coronary artery disease or dilated cardiomyopathy [29], which involves however differ-
ent mechanisms from the compensated hypertrophy due to arterial hypertension or aortic ste-
nosis. In a mouse model of cardiac remodeling induced by transverse aortic constriction,
administration of an anti-CX3CL1 neutralizing antibody significantly slows hypertrophy pro-
gression [26]. In our study, expression of CX3CR1, the CX3CL1 receptor, was higher in the
aortic-banded group on D3, D5, and D7, i.e. in the inflammatory phase and early in the hyper-
trophic phase. It was thus the longest lasting receptor mRNA overexpression in our study.
CX3CR1 is reported to distinguish between monocyte/macrophage populations [14]. These
authors have suggested that increased expression of CX3CR1 at the cell surface of the anti-
inflammatory M2 macrophages might further promote their adhesion to the endothelium-
expressing membrane CX3CL1. Targeting the CX3CR1 receptor might thus contribute to
decreasing the accumulation of inflammatory cells in the left ventricle, which progresses to
fibrosis.
In our LVH model, neither CXCL12 mRNA (SDF-1a, Stromal cell-derived factor 1a) nor its
receptor CXCR4 was expressed. This finding contrasts with the upregulation of CXCL12 and
CXCR4, respectively in the plasma and left ventricles, in patients with chronic heart failure due
to coronary artery disease or dilated cardiomyopathy and in two mouse models of cardiac
hypertrophy, one due to transaortic constriction and the other using transgenic RacET mice
with cardiac overexpression of the small GTPase Rac1 [32].
Finally, the only downregulated gene we found in our study was cxcl11, an IFNg-inducible
chemokine [55]. No IFNg expression was observed in our model. Little information is available
on this chemokine’s potential role in cardiac disease. Elevated serum levels are associated with
the development of coronary artery disease after heart transplantation [56] and with the pro-
gression from asymptomatic to symptomatic diastolic left ventricular dysfunction in hyperten-
sive patients [57]. It will be interesting to analyze the expression of CXCL11 in LV later in our
model, during development of the cardiac decompensation. The role of CXCL11 and its down-
regulation in the early phase of rat LVH model requires further investigation.
We must underline that the LVH studied during the observation period in our model was in
its compensated stage, as shown by the echocardiographic analysis, which detected no cardiac
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dysfunction. Mice with inadequate cardiac hypertrophic response show early heart failure and
die earlier [58]. Chemokines are thought to act directly on resident cardiomyocytes to induce
cardioprotective mechanisms, as reported for CCL2 overexpression, which protects cultured
cardiomyocytes from hypoxia-induced cell death [59, 60]. Likewise, the association between
the overexpression of CCL2/MCP1 in MHC-MCP1 mice and improved cardiac tissue repair
after myocardial infarction suggests that this chemokine plays a role in tissue remodeling after
damage [61].
The information provided by our study is important for understanding the development of
the inflammatory phase of cardiac hypertrophy as well as the chemokine/receptor interactions.
The protein expression of these chemokines and receptors together with the presence of infil-
trated immune and inflammatory cells will add new insights into the role of these chemokines
in LVH. Moreover, an analysis of expression of chemokines and receptors in a failing heart
model, i.e. during the transition from compensated to decompensated LVH, would therefore
be useful for delineating their roles in both stages of hypertrophy.
In conclusion, our rat model of LVH without cardiac dysfunction exhibited an inflamma-
tory phase at D3-D5 after aortic banding and then evolved into a phase with a clear hypertro-
phic phenotype at D7-D14. Comprehensive analysis of chemokine and receptor mRNA
expression revealed overexpression during the inflammatory phase, followed by a return to
baseline levels in the hypertrophic phase. Most of the overexpressed chemokines belong to the
monocyte/macrophage chemotactic families MIP and MCP. Further elucidation of the role of
these chemokines in the inflammatory response (recruitment of proinflammatory cells) and/or
hypertrophic compensatory mechanisms (protection of resident cardiomyocytes) is now neces-
sary to understand whether targeting the chemokine network during pressure overload might
usefully supplement the blockage of the hypertrophic signaling pathways currently available in
clinical settings.
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